No black box warning on record for Hydralazine Hydrochloride

As of the latest FDA labeling reviewed, Hydralazine Hydrochloride (HYDRALAZINE HYDROCHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Hydralazine Hydrochloride medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS In a few patients hydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many year

No black box warning on record for Hydralazine Hydrochloride

Other warnings & precautions

WARNINGS In a few patients hydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many year

Hydralazine Hydrochloride Black Box Warning

No black box warning on record for Hydralazine Hydrochloride

Other warnings & precautions

Hydralazine Hydrochloride Black Box Warning

No black box warning on record for Hydralazine Hydrochloride

Other warnings & precautions